Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal
Alnylam Pharmaceuticals has forged a discovery collaboration worth up to $1.23bn with cardiovascular disease specialist, Tenaya Therapeutics. Through this partnership,…
06 Mar 2026
J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma
Johnson & Johnson (J&J) has announced the US Food and Drug Administration (FDA) approval for the combination of Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adults with relapsed…
06 Mar 2026
Liberate Bio gains licences for myeloid-specific CAR design patents
Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for myeloid cells, such as monocytes and macrophages. The licences sourced…
05 Mar 2026
Moderna pays up to $2.25bn to settle drug delivery tech patent lawsuit
Moderna has agreed to pay up to $2.25bn to settle a patent infringement lawsuit with Genevant and Arbutus, ending a prolonged legal battle between the companies. The Massachusetts-based pharma has…
05 Mar 2026
CordenPharma leases space at Flatiron Park for peptides development
US-based CordenPharma Colorado has leased a 64,000ft² space at BioMed Realty’s Flatiron Park’s 5505 Central, which marks Boulder’s first purpose-built speculative lab building, for peptides development. CordenPharma Colorado will occupy…
05 Mar 2026
Pharmaceutical Technology’s parent company GlobalData moves to Main Market of LSE
LONDON, 05 March 2026 – GlobalData Plc, the trusted intelligence platform and parent company of Pharmaceutical Technology, today moves from AIM to the Main Market of the London Stock Exchange. The move reflects the scale and maturity…
05 Mar 2026
Affinia receives FDA fast track designation for AFTX-201
Affinia Therapeutics has received the US Food and Drug Administration (FDA) fast track designation (FTD) for AFTX-201, a genetic medicine under investigation for treating Bcl-2-associated athanogene 3 (BAG3)-associated dilated cardiomyopathy…